Executive Summary: The global Urothelial Cancer Drugs market size was valued at USD 1.44 billion in 2024 and is expected to reach USD 2.80 billion by 2032, at a CAGR of 8.7% during the forecast period. This growth is driven by the rising global burden of bladder cancer, significant advances in immunotherapy, and expanding access to oncology treatment across both developed and emerging...